The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Innovative approaches to optimizing the delivery of vancomycin in individual patients
Open accessAbstract
The delivery of personalized antimicrobial therapy is a critical component in the treatment of patients with invasive infections. Vancomycin, the drug of choice for infections due to methicillin-resistant Staphylococcus aureus, requires the use of therapeutic drug monitoring (TDM) for delivery of optimal therapy. Current guidance on vancomycin TDM includes the measurement of a trough concentration as a surrogate for achieving an AUC to minimum inhibitory concentration (MIC) by broth microdilution (AUC/MICBMD) ratio≥400. Although trough-only monitoring has been widely integrated into clinical practice, there is a high degree of inter-individual variability between a measured trough concentration and the actual AUC value. The therapeutic discordance between AUC and trough may lead to suboptimal outcomes among patients with infections due to less susceptible pathogens or unnecessarily increase the probability of acute kidney injury (AKI) in others. Given the potentially narrow vancomycin AUC range for optimal effect and minimal AKI, clinicians need a "real-time" system to predict accurately the AUC with limited pharmacokinetic (PK) sampling. This article reviews two innovative approaches for calculating the vancomycin AUC in clinical practice based on one or two drug concentrations. One such approach involves the use of Bayesian computer software programs to estimate the "true" vancomycin AUC value with minimal PK sampling and provide AUC-guided dosing recommendations at the bedside. An alternative involves use of two concentrations (peak and trough) and simple analytic equations to estimate AUC values. Both approaches provide considerable improvements over the current trough-only concentration monitoring method.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir034 · Cited by 1,599
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Levine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774
Moise-Broder, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00005 · Cited by 757
van Hal, S. J., Paterson, D. L., & Lodise, T. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-12 · Cited by 639
Self-citationLodise, T. P., Lomaestro, B., Graves, J., & Drusano, G. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01602-07 · Cited by 574
Self-citationWunderink, R. G., Niederman, M. S., Kollef, M. H., Shorr, A. F., Kunkel, M. J., Baruch, A., McGee, W. T., Reisman, A., & Chastre, J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir895 · Cited by 570
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556
Lodise, T. P., Patel, N., Lomaestro, B. M., Rodvold, K. A., & Drusano, G. L. (2009) · Clinical Infectious Diseases · doi:10.1086/600884 · Cited by 554
Self-citationLodise, T. P., Graves, J., Evans, A., Graffunder, E., Helmecke, M., Lomaestro, B. M., & Stellrecht, K. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00113-08 · Cited by 553
Self-citationvan Hal, S. J., Lodise, T. P., & Paterson, D. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir935 · Cited by 512
Self-citationKullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir124 · Cited by 463 · cited 1×
“However, at the upper end of the trough continuum, treatment failure again increased in patients with vancomycin trough concentrations N20 mg/L [20].”
BackgroundA suggested approach to once‐daily aminoglycoside dosing.
Begg, E., Barclay, M., & Duffull, S. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05719.x · Cited by 420
Rybak, M. J., Lomaestro, B. M., Rotschafer, J. C., Moellering, R. C., Craig, W. A., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.11.1275 · Cited by 403
Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?
Neely, M. N., Youn, G., Jones, B., Jelliffe, R. W., Drusano, G. L., Rodvold, K. A., & Lodise, T. P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-13 · Cited by 392
Self-citationNephrotoxicity of vancomycin, alone and with an aminoglycoside
Rybak, M. J., Albrecht, L. M., Boike, S. C., & Chandrasekar, P. H. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/25.4.679 · Cited by 388
Sawchuk, R. J., & Zaske, D. E. (1976) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01086153 · Cited by 361
Jeffres, M. N., Isakow, W., Doherty, J. A., Micek, S. T., & Kollef, M. H. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.06.014 · Cited by 334
Historical Yearly Usage of Vancomycin
Kirst, H. A., Thompson, D. G., & Nicas, T. I. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1303 · Cited by 276
Vancomycin: A 50-Year Reassessment
Moellering, R. C. (2006) · Clinical Infectious Diseases · doi:10.1086/491708 · Cited by 275
Gabrielsson, J., & Weiner, D. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-050-2_16 · Cited by 265
Bosso, J. A., Nappi, J., Rudisill, C., Wellein, M., Bookstaver, P. B., Swindler, J., & Mauldin, P. D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00168-11 · Cited by 252
Vancomycin pharmacokinetics in patients with various degrees of renal function
Rodvold, K. A., Blum, R. A., Fischer, J. H., Zokufa, H. Z., Rotschafer, J. C., Crossley, K. B., & Riff, L. J. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.6.848 · Cited by 249
Self-citationVancomycin: We Can't Get There From Here
Patel, N., Pai, M. P., Rodvold, K. A., Lomaestro, B., Drusano, G. L., & Lodise, T. P. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir078 · Cited by 247
Self-citationVancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia
Holmes, N. E., Turnidge, J. D., Munckhof, W. J., Robinson, J. O., Korman, T. M., O'Sullivan, M. V. N., Anderson, T. L., Roberts, S. A., Warren, S. J. C., Gao, W., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01485-12 · Cited by 224
Incidence and Risk Factors Influencing the Development of Vancomycin Nephrotoxicity in Children
McKamy, S., Hernandez, E., Jahng, M., Moriwaki, T., Deveikis, A., & Le, J. (2011) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2010.08.019 · Cited by 186
Mohr, J. F., & Murray, B. E. (2007) · Clinical Infectious Diseases · doi:10.1086/518451 · Cited by 185
Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy
Wong-Beringer, A., Joo, J., Tse, E., & Beringer, P. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.10.013 · Cited by 178
A prospective study of adverse reactions associated with vancomycin therapy
Sorrell, T. C., & Collignon, P. J. (1985) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/16.2.235 · Cited by 175
Lodise, T. P., Drusano, G. L., Zasowski, E., Dihmess, A., Lazariu, V., Cosler, L., & McNutt, L.-A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu398 · Cited by 167
Self-citationBenchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer Tools
Fuchs, A., Csajka, C., Thoma, Y., Buclin, T., & Widmer, N. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0020-y · Cited by 165
Ingram, P. R., Lye, D. C., Tambyah, P. A., Goh, W. P., Tam, V. H., & Fisher, D. A. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn080 · Cited by 163
Cano, E. L., Haque, N. Z., Welch, V. L., Cely, C. M., Peyrani, P., Scerpella, E. G., Ford, K. D., Zervos, M. J., Ramirez, J. A., & Kett, D. H. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.12.013 · Cited by 161
Increasing Vancomycin Serum Trough Concentrations and Incidence of Nephrotoxicity
Pritchard, L., Baker, C., Leggett, J., Sehdev, P., Brown, A., & Bayley, K. B. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.07.025 · Cited by 161
Jelliffe, R. W., Schumitzky, A., Guilder, M. V., Liu, M., Hu, L. H., Maire, P. H., Gomis, P., Barbaut, X., & Tahani, B. (1993) · PubMed · Cited by 149
Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination
Goetz, M. B., & Sayers, J. F. B. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/32.2.325 · Cited by 145
Vancomycin-Associated Nephrotoxicity: Grave Concern or Death by Character Assassination?
Hazlewood, K. A., Brouse, S. D., Pitcher, W. D., & Hall, R. G. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.05.031 · Cited by 139
Individualizing Drug Dosage Regimens
Jelliffe, R. W., Schumitzky, A., Guilder, M. V., Liu, M., Hu, L., Maire, P. H., Gomis, P., Barbaut, X., & Tahani, B. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199310000-00005 · Cited by 139
Cimino, M. A., Rotstein, C., Slaughter, R. L., & Emrich, L. J. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90947-8 · Cited by 128
Zimmermann, A. E., Katona, B. G., & Plaisance, K. I. (1995) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1995.tb04335.x · Cited by 122
Suzuki, Y., Kawasaki, K., Sato, Y., Tokimatsu, I., Itoh, H., Hiramatsu, K., Takeyama, M., & Kadota, J. (2012) · Chemotherapy · doi:10.1159/000343162 · Cited by 110
Elting, L. S., Rubenstein, E. B., Kurtin, D., Rolston, K. V. I., Fangtang, J. T., Martin, C. G., RAAD, I. I., Whimbey, E. E., Manzullo, E. F., & Bodey, G. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2597::aid-cncr27>3.0.co;2-l · Cited by 109
Kullar, R., Leonard, S. N., Davis, S. L., Delgado, G., Pogue, J. M., Wahby, K. A., Falcione, B. A., & Rybak, M. J. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.5.441 · Cited by 106
Hermsen, E. D., Hanson, M., Sankaranarayanan, J., Stoner, J. A., Florescu, M. C., & Rupp, M. E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903413514 · Cited by 102
Mild Nephrotoxicity Associated With Vancomycin Use
Downs, N. J. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390080053013 · Cited by 102
Minejima, E., Choi, J. J., Beringer, P. M., Lou, M., Tse, E., & Wong‐Beringer, A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00173-11 · Cited by 94
Darko, W., Medicis, J. J., Smith, A., Guharoy, R., & Lehmann, D. F. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.5.643.32199 · Cited by 81
A Bayesian Approach to Tracking Patients Having Changing Pharmacokinetic Parameters
Bayard, D. S., & Jelliffe, R. W. (2004) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/b:jopa.0000029490.76908.0c · Cited by 64
Cohen, E. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.1.155 · Cited by 57
Spapen, H. D., van Doorn, K. J., Diltoer, M., Verbrugghe, W., Jacobs, R., Dobbeleir, N., Honoré, P. M., & Jorens, P. G. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-26 · Cited by 52
Pai, M. P., Russo, A., Novelli, A., Venditti, M., & Falcone, M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02355-14 · Cited by 50
Self-citationKralovicová, K., Spanik, S., Halko, J., et al. (1997) · Journal of Chemotherapy · doi:10.1179/joc.1997.9.6.420 · Cited by 39
Chung, J., Oh, J. M., Cho, E. M., et al. (2011) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1103900608 · Cited by 38
Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans
Prabaker, K. K., Tran, T. P. ‐., Pratummas, T., Goetz, M. B., & Graber, C. J. (2011) · Journal of Hospital Medicine · doi:10.1002/jhm.946 · Cited by 37
Marinho, D. S., Huf, G., Ferreira, B. L., Castro, H. C., Rodrigues, C. R., de Sousa, V. P., & Cabral, L. M. (2011) · BMC Research Notes · doi:10.1186/1756-0500-4-236 · Cited by 34
Fisher, B. T., Zaoutis, T. E., Leckerman, K. H., Localio, R. A., & Aplenc, R. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22601 · Cited by 33
Pai, M. P., & Rodvold, K. A. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.10.011 · Cited by 31
Self-citationAubron, C., Corallo, C., Nunn, M. O., Dooley, M. J., & Cheng, A. C. (2011) · Annals of Pharmacotherapy · doi:10.1177/106002801104501001 · Cited by 29
Cited by
Rybak, M. J., Le, J., Lodise, T. P., Levine, D. P., Bradley, J. S., Liu, C., Mueller, B. A., Pai, M. P., Wong-Beringer, A., Rotschafer, J. C., et al. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa036 · Cited by 1,202
Self-citationNeely, M. N., Kato, L., Youn, G., Kraler, L., Bayard, D., van Guilder, M., Schumitzky, A., Yamada, W., Jones, B., & Minejima, E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02042-17 · Cited by 359
Self-citationThabit, A. K., Crandon, J. L., & Nicolau, D. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.993381 · Cited by 160
Turner, R. B., Kojiro, K., Shephard, E. A., Won, R., Chang, E., Chan, D., & Elbarbry, F. (2018) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2191 · Cited by 135
Beavers, D. P., Hsieh, K. L., Kitzman, D. W., Kritchevsky, S. B., Messier, S. P., Neiberg, R. H., Nicklas, B. J., Rejeski, W. J., & Beavers, K. M. (2022) · PLOS ONE · doi:10.1371/journal.pone.0267779 · Cited by 7
Metadata
- Authors
- Pai, M. P., Neely, M., Rodvold, K. A., & Lodise, T. P.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 77
- Pages
- 50-57
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2057605178
- Cited by
- 292
- References
- 63
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.